Glycosylated nanocarriers: Novel avenue for tuberculosis treatment
Design of glycosylated nanocarriers of Rifampicin for active targeting to infected alveolar macrophages
(Sprache: Englisch)
Tuberculosis (TB), an infectious disease caused by the bacillus Mycobacterium tuberculosis.According to world Health Organization (WHO) global TB report 2017, India accounts for about a quarter of the global TB burden.As per current therapy point of view,...
Leider schon ausverkauft
versandkostenfrei
Buch
61.90 €
Produktdetails
Produktinformationen zu „Glycosylated nanocarriers: Novel avenue for tuberculosis treatment “
Klappentext zu „Glycosylated nanocarriers: Novel avenue for tuberculosis treatment “
Tuberculosis (TB), an infectious disease caused by the bacillus Mycobacterium tuberculosis.According to world Health Organization (WHO) global TB report 2017, India accounts for about a quarter of the global TB burden.As per current therapy point of view, combination of antibiotics administered either by oral or parenteral route.The pulmonary route is noninvasive method of drug delivery, for both local and systemic delivery of an active pharmaceutical ingredient. Rifampicin (RIF) is one of the first line drug used in treatment of tuberculosis. The dose of RIF when orally given is 10mg/kg (maximum 600mg/day) daily. Since the minimum inhibitory concentration of RIF is only 0.005-0.2 mig/ml after a usual 600mg dose, there is a need to decrease the dose and thus decreasing the high dose related side effects such as skin rashes, immunological reactions, hepatotoxicity etc. Lung targeted drug delivery system is one of the approach to reduce dose related side effects of RIF. This overview enabled to conclude that Nanostructured Lipid Carrier could serve as viable option in targeting M. tb infected alveolar macrophages by pulmonary route.
Autoren-Porträt von Vipul Sansare
Sansare, VipulMr. Vipul Sansare,obtained his B.Pharm and M.Pharm degrees from university of Mumbai and registered for PhD in Jaipur National University, Rajastan. At present he is serving as Asst. Professor of Pharmaceutics at Indira Institute of Pharmacy, Sadavali, Maharashtra. He is author of many national and international research papers.
Bibliographische Angaben
- Autor: Vipul Sansare
- 2019, 132 Seiten, Maße: 22 cm, Kartoniert (TB), Englisch
- Verlag: LAP Lambert Academic Publishing
- ISBN-10: 6200117071
- ISBN-13: 9786200117076
Sprache:
Englisch
Kommentar zu "Glycosylated nanocarriers: Novel avenue for tuberculosis treatment"
0 Gebrauchte Artikel zu „Glycosylated nanocarriers: Novel avenue for tuberculosis treatment“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Glycosylated nanocarriers: Novel avenue for tuberculosis treatment".
Kommentar verfassen